Aktuelle smitsomme sygdomme
Søgeord (covid-19) valgt.
617 emner vises.
Maria Siopi, Panagiota-Christina Georgiou, Paschalis Paranos, Maria-Ioanna Beredaki, Aikaterini Tarpatzi, Eleni Kalogeropoulou, Sofia Damianidou, Alexandra Vasilakopoulou, Polyxeni Karakosta, Spyros Pournaras and Joseph Meletiadis
Eurosurveillance latest updates, 20.07.2024
Tilføjet 20.07.2024
BackgroundThe COVID-19 pandemic and the emergence of Candida auris have changed the epidemiological landscape of candidaemia worldwide. AimWe compared the epidemiological trends of candidaemia in a Greek tertiary academic hospital before (2009–2018) and during the early COVID-19 (2020–2021) and late COVID-19/early post-pandemic (2022–2023) era. MethodsIncidence rates, species distribution, antifungal susceptibility profile and antifungal consumption were recorded, and one-way ANOVA or Fisher’s exact test performed. Species were identified by MALDI-ToF MS, and in vitro susceptibility determined with CLSI M27-Ed4 for C. auris and the EUCAST-E.DEF 7.3.2 for other Candida spp. ResultsIn total, 370 candidaemia episodes were recorded during the COVID-19 pandemic. Infection incidence (2.0 episodes/10,000 hospital bed days before, 3.9 during the early and 5.1 during the late COVID-19 era, p
Læs mereLouise Marron, Alberto Mateo-Urdiales, Joan O’Donnell, Eve Robinson and Lisa Domegan
Eurosurveillance latest updates, 12.07.2024
Tilføjet 12.07.2024
BackgroundAs Ireland prepared for an autumn 2023 COVID-19 vaccination booster campaign, there was concern that vaccine fatigue would affect uptake, which has been abating. AimThis study aimed to quantify the direct impact of the COVID-19 vaccination programme in Ireland on averted COVID-19-related outcomes including symptomatic presentations to primary care/community testing centres, emergency department (ED) presentations, hospitalisations, intensive care unit (ICU) admissions and deaths, in individuals aged ≥ 50 years, during Omicron dominance. MethodsWe conducted a retrospective observational COVID-19 vaccine impact study in December 2021–March 2023 in Ireland. We used national data on notified outcomes and vaccine coverage, as well as vaccine effectiveness (VE) estimates, sourced from the World Health Organization’s live systematic review of VE, to estimate the count and prevented fraction of outcomes in ≥ 50-year-olds averted by the COVID-19 vaccination programme in this age group. ResultsThe COVID-19 vaccination programme averted 48,551 symptomatic COVID-19 presentations to primary care/community testing centres (36% of cases expected in the absence of vaccination), 9,517 ED presentations (53% of expected), 102,160 hospitalisations (81% of expected), 3,303 ICU admissions (89% of expected) and 15,985 deaths (87% of expected). ConclusionsWhen Omicron predominated, the COVID-19 vaccination programme averted symptomatic and severe COVID-19 cases, including deaths due to COVID-19. In line with other international vaccine impact studies, these findings emphasise the benefits of COVID-19 vaccination for population health and the healthcare system and are relevant for informing COVID-19 booster vaccination programmes, pandemic preparedness and communicating the reason for and importance of COVID-19 vaccination in Ireland and internationally.
Læs mereLaila Toro, Henriette de Valk, Laura Zanetti, Caroline Huot, Arnaud Tarantola, Nelly Fournet, Laurent Moulin, Ali Atoui, Benoît Gassilloud, Damien Mouly and Frédéric Jourdain
Eurosurveillance latest updates, 12.07.2024
Tilføjet 12.07.2024
BackgroundWastewater surveillance is an effective approach to monitor population health, as exemplified by its role throughout the COVID-19 pandemic. AimThis study explores the possibility of extending wastewater surveillance to the Paris 2024 Olympic and Paralympic Games, focusing on identifying priority pathogen targets that are relevant and feasible to monitor in wastewater for these events. MethodsA list of 60 pathogens of interest for general public health surveillance for the Games was compiled. Each pathogen was evaluated against three inclusion criteria: (A) analytical feasibility; (B) relevance, i.e. with regards to the specificities of the event and the characteristics of the pathogen; and (C) added value to inform public health decision-making. Analytical feasibility was assessed through evidence from peer-reviewed publications demonstrating the detectability of pathogens in sewage, refining the initial list to 25 pathogens. Criteria B and C were evaluated via expert opinion using the Delphi method. The panel consisting of some 30 experts proposed five additional pathogens meeting criterion A, totalling 30 pathogens assessed throughout the three-round iterative questionnaire. Pathogens failing to reach 70% group consensus threshold underwent further deliberation by a subgroup of experts. ResultsSix priority targets suitable for wastewater surveillance during the Games were successfully identified: poliovirus, influenza A virus, influenza B virus, mpox virus, SARS-CoV-2 and measles virus. ConclusionThis study introduced a model framework for identifying context-specific wastewater surveillance targets for a mass gathering. Successful implementation of a wastewater surveillance plan for Paris 2024 could incentivise similar monitoring efforts for other mass gatherings globally.
Læs mereMaaike C Swets, Annabel Niessen, Emilie P Buddingh, Ann CTM Vossen, Karin Ellen Veldkamp, Irene K Veldhuijzen, Mark GJ de Boer and Geert H Groeneveld
Eurosurveillance latest updates, 5.07.2024
Tilføjet 5.07.2024
BackgroundEffective pandemic preparedness requires robust severe acute respiratory infection (SARI) surveillance. However, identifying SARI patients based on symptoms is time-consuming. Using the number of reverse transcription (RT)-PCR tests or contact and droplet precaution labels as a proxy for SARI could accurately reflect the epidemiology of patients presenting with SARI. AimWe aimed to compare the number of RT-PCR tests, contact and droplet precaution labels and SARI-related International Classification of Disease (ICD)-10 codes and evaluate their use as surveillance indicators. MethodsPatients from all age groups hospitalised at Leiden University Medical Center between 1 January 2017 up to and including 30 April 2023 were eligible for inclusion. We used a clinical data collection tool to extract data from electronic medical records. For each surveillance indicator, we plotted the absolute count for each week, the incidence proportion per week and the correlation between the three surveillance indicators. ResultsWe included 117,404 hospital admissions. The three surveillance indicators generally followed a similar pattern before and during the COVID-19 pandemic. The correlation was highest between contact and droplet precaution labels and ICD-10 diagnostic codes (Pearson correlation coefficient: 0.84). There was a strong increase in the number of RT-PCR tests after the start of the COVID-19 pandemic. DiscussionAll three surveillance indicators have advantages and disadvantages. ICD-10 diagnostic codes are suitable but are subject to reporting delays. Contact and droplet precaution labels are a feasible option for automated SARI surveillance, since these reflect trends in SARI incidence and may be available real-time.
Læs mereMedscape Infectious Diseases, 1.07.2024
Tilføjet 1.07.2024
AstraZeneca said on Monday that the European Union drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug,... Reuters Health Information
Læs mereMedscape Infectious Diseases, 28.06.2024
Tilføjet 28.06.2024
The U.S. Centers for Disease Control and Prevention has recommended that individuals aged six months and older should be given an updated COVID-19 vaccine for the 2024-25... Reuters Health Information
Læs mereBianca Schulte, Enrico Richter, Antonia Büning, Maximilian Baum, Annika Breuer, Jasmin Zorn, Julia König, Melanie Geiger, Monika Eschbach-Bludau, Johanna Heuser, Dominik Zölzer, Marek Korencak, Ronja Hollstein, Eva Beins, Dorian Emmert, Souhaib Aldabbagh, Anna Maria Eis-Hübinger and Hendrik Streeck
Eurosurveillance latest updates, 28.06.2024
Tilføjet 28.06.2024
BackgroundSince its emergence in December 2019, over 700 million people worldwide have been infected with SARS-CoV-2 up to May 2024. While early rollout of mRNA vaccines against COVID-19 has saved many lives, there was increasing immune escape of new virus variants. Longitudinal monitoring of population-wide SARS-CoV-2 antibody responses from regular sample collection irrespective of symptoms provides representative data on infection and seroconversion/seroreversion rates. AimTo examine adaptive and cellular immune responses of a German SARS-CoV-2 outbreak cohort through several waves of infection with different virus variants. MethodsUtilising a 31-month longitudinal seroepidemiological study (n = 1,446; mean age: 50 years, range: 2–103) initiated during the first SARS-CoV-2 superspreading event (February 2020) in Heinsberg, Germany, we analysed acute infection, seroconversion and virus neutralisation at five follow-up visits between October 2020 and November 2022; cellular and cross-protective immunity against SARS-CoV-2 Omicron variants were also examined. ResultsSARS-CoV-2 spike (S)-specific IgAs decreased shortly after infection, while IgGs remained stable. Both increased significantly after vaccination. We predict an 18-month half-life of S IgGs upon infection. Nucleocapsid (N)-specific responses declined over 12 months post-infection but increased (p
Læs mereMedscape Infectious Diseases, 25.06.2024
Tilføjet 25.06.2024
The COVID-19 pandemic has been associated with reported declines in cancer screenings. Now a new study suggested these decreases extended through 2022 for cervical cancer screening in particular. Medscape Medical News
Læs mereMinke R Holwerda, Christina E Hoeve, Anne J Huiberts, Gerco den Hartog, Hester E de Melker, Susan van den Hof and Mirjam J Knol
Eurosurveillance latest updates, 22.06.2024
Tilføjet 22.06.2024
BackgroundNon-severe adverse events (AE) including pain at injection site or fever are common after COVID-19 vaccination. AimTo describe determinants of AE after COVID-19 vaccination and investigate the association between AE and pre- and post-vaccination antibody concentrations. MethodsParticipants of an ongoing prospective cohort study (VASCO) completed a questionnaire on AE within 2 months after vaccination and provided 6 monthly serum samples during May 2021–November 2022. Logistic regression analyses were performed to investigate AE determinants after mRNA vaccination, including pre-vaccination Ig antibody concentrations against the SARS-CoV-2 spike protein receptor binding domain. Multivariable linear regression was performed in SARS-CoV-2-naive participants to assess the association between AE and log-transformed antibody concentrations 3–8 weeks after mRNA vaccination. ResultsWe received 47,947 completed AE questionnaires by 28,032 participants. In 42% and 34% of questionnaires, injection site and systemic AE were reported, respectively. In 2.2% of questionnaires, participants sought medical attention. AE were reported more frequently by women, younger participants (
Læs mereECDC
ECDC COVID-19 updates, 21.06.2024
Tilføjet 21.06.2024
This After-Action Review (AAR) investigates the use of evidence in Norway’s advice-making process about school continuity in secondary (13–15 years old) and upper secondary schools (16–18 years old) during the COVID-19 pandemic.
Læs mereMedscape Infectious Diseases, 19.06.2024
Tilføjet 19.06.2024
Is a slow recovery from COVID-19 the lingering effects of a bad infection or the start of a new syndrome? Medscape
Læs mereMedscape Infectious Diseases, 13.06.2024
Tilføjet 13.06.2024
Moderna said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared... Reuters Health Information
Læs mereStatens Serum Institut, 11.06.2024
Tilføjet 11.06.2024
Efter et dyk i forbruget under covid-19-pandemien bruger vi igen mere antibiotika i Danmark. Stigningen ses både hos de yngste og ældste borgere, viser nye tal fra DANMAP-programmet.
Læs mereOlga Frank, David Acitores Balboa, Maria Novatchkova, Ezgi Özkan, Marcus Martin Strobl, Ramesh Yelagandula, Tanino Guiseppe Albanese, Lukas Endler, Fabian Amman, Vera Felsenstein, Milanka Gavrilovic, Melanie Acosta, Timothej Patocka, Alexander Vogt, Ido Tamir, Julia Klikovits, Alexander Zoufaly, Tamara Seitz, Manuela Födinger, Andreas Bergthaler, Alexander Indra, Daniela Schmid, Peter Klimek, Alexander Stark, Franz Allerberger, Bernhard Benka, Katharina Reich, Luisa Cochella and Ulrich Elling
Eurosurveillance latest updates, 7.06.2024
Tilføjet 7.06.2024
BackgroundThe COVID-19 pandemic was largely driven by genetic mutations of SARS-CoV-2, leading in some instances to enhanced infectiousness of the virus or its capacity to evade the host immune system. To closely monitor SARS-CoV-2 evolution and resulting variants at genomic-level, an innovative pipeline termed SARSeq was developed in Austria. AimWe discuss technical aspects of the SARSeq pipeline, describe its performance and present noteworthy results it enabled during the pandemic in Austria. MethodsThe SARSeq pipeline was set up as a collaboration between private and public clinical diagnostic laboratories, a public health agency, and an academic institution. Representative SARS-CoV-2 positive specimens from each of the nine Austrian provinces were obtained from SARS-CoV-2 testing laboratories and processed centrally in an academic setting for S-gene sequencing and analysis. ResultsSARS-CoV-2 sequences from up to 2,880 cases weekly resulted in 222,784 characterised case samples in January 2021–March 2023. Consequently, Austria delivered the fourth densest genomic surveillance worldwide in a very resource-efficient manner. While most SARS-CoV-2 variants during the study showed comparable kinetic behaviour in all of Austria, some, like Beta, had a more focused spread. This highlighted multifaceted aspects of local population-level acquired immunity. The nationwide surveillance system enabled reliable nowcasting. Measured early growth kinetics of variants were predictive of later incidence peaks. ConclusionWith low automation, labour, and cost requirements, SARSeq is adaptable to monitor other pathogens and advantageous even for resource-limited countries. This multiplexed genomic surveillance system has potential as a rapid response tool for future emerging threats.
Læs mereMedscape Infectious Diseases, 6.06.2024
Tilføjet 6.06.2024
Advisers to the U.S. Food and Drug Administration on Wednesday unanimously voted in favor of recommending that COVID-19 vaccines for 2024-25 should target a strain within... Reuters Health Information
Læs mereMedscape Infectious Diseases, 6.06.2024
Tilføjet 6.06.2024
Former top U.S. infectious disease expert Dr. Anthony Fauci strongly denied suppressing the theory that COVID-19 originated from a lab leak in China, telling lawmakers he... Reuters Health Information
Læs mereMedscape Infectious Diseases, 4.06.2024
Tilføjet 4.06.2024
For the first time, an mRNA vaccine has been approved for an indication other than COVID-19. The vaccine will join a couple other immunizations currently on the market for respiratory syncytial virus. Medscape Medical News
Læs mereMarlène Guillet, Ariane Bas, Marjorie Lacoste, Céline Ricard, Catherine Visse, Valérie Barlet, Lucile Malard, Sophie Le Cam, Pascal Morel, Xavier de Lamballerie, Syria Laperche and Pierre Gallian
Eurosurveillance latest updates, 26.05.2024
Tilføjet 26.05.2024
In France, blood donations are tested in pools of 96 samples for parvovirus B19 (B19V) DNA to discard plasma for fractionation when it contains high viral loads. Between January 2015 and March 2024, B19V-positive donations decreased during the COVID-19 pandemic, followed by a strong rebound in 2023 and unusually high circulation during winter 2023/24 (ca 10 times higher December 2023–March 2024 vs the pre-pandemic period). Variations over time are probably related to measures implemented to limit SARS-CoV-2 spread.
Læs mereMarlène Guillet, Ariane Bas, Marjorie Lacoste, Céline Ricard, Catherine Visse, Valérie Barlet, Lucile Malard, Sophie Le Cam, Pascal Morel, Xavier de Lamballerie, Syria Laperche and Pierre Gallian
Eurosurveillance latest updates, 24.05.2024
Tilføjet 24.05.2024
In France, blood donations are tested in pools of 96 samples for parvovirus B19 (B19V) DNA to discard plasma for fractionation when it contains high viral loads. Between January 2015 and March 2024, B19V-positive donations decreased during the COVID-19 pandemic, followed by a strong rebound in 2023 and unusually high circulation during winter 2023/24 (ca 10 times higher December 2023–March 2024 vs the pre-pandemic period). Variations over time are probably related to measures implemented to limit SARS-CoV-2 spread.
Læs mereFranziska Hommes, Achim Dörre, Susanne C Behnke, Klaus Stark and Mirko Faber
Eurosurveillance latest updates, 17.05.2024
Tilføjet 17.05.2024
BackgroundGiardia duodenalis is a major cause of gastroenteritis globally, and is the most common food- and waterborne parasitic infection in Europe. AimTo describe the epidemiology of reported acute giardiasis cases in Germany and compare demographic and clinical characteristics between imported and autochthonous cases. MethodsWe conducted a descriptive analysis of giardiasis cases that fulfilled the national case definition and were reported between January 2002 and December 2021. We defined an imported case as having at least one place of exposure abroad in the 3–25 days before symptom onset. We analysed case numbers and incidence by age, sex, month reported and geographic region, both overall and stratified by autochthonous and imported cases. ResultsFrom 2002 to 2021, 72,318 giardiasis cases were reported in Germany, corresponding to a mean annual incidence of 4.4 per 100,000 population. Annual incidence gradually decreased since 2013, declining sharply during the COVID-19 pandemic in 2020–21. Of 69,345 cases reported between 2002 and 2019, 35% were imported. Incidence of autochthonous cases (overall yearly mean: 3.1/100,000) was highest in males and young children (
Læs mereWei Cai, Sophie Köndgen, Kristin Tolksdorf, Ralf Dürrwald, Barbara Biere, Walter Haas, Thorsten Wolff, Silke Buda and Janine Reiche
Eurosurveillance latest updates, 17.05.2024
Tilføjet 17.05.2024
Statens Serum Institut, 16.05.2024
Tilføjet 16.05.2024
Nyt studie viser, at efterårets covid-19-vaccine er mindre effektiv over for de nye covid-varianter, der har domineret smittebilledet den forgangne vinter. Men vaccinen har stadig en væsentlig effekt.
Læs mereMedscape Infectious Diseases, 16.05.2024
Tilføjet 16.05.2024
CDC experts share what clinicians should know about COVID-19 prevention in immunocompromised patients. CDC Expert Commentary
Læs mereMorbidity and Mortality Weekly Report (MMWR), 14.05.2024
Tilføjet 14.05.2024
Medscape Infectious Diseases, 26.04.2024
Tilføjet 26.04.2024
The drugs are intended to treat several types of arthritis, psoriasis, COVID-19, and Crohn\'s disease. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 26.04.2024
Tilføjet 26.04.2024
This report describes a recommendation from the Advisory Committee on Immunization Practices that all people ages ≥65 years and older receive one additional dose of any updated (2023-2024 Formula) COVID-19 vaccine.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 26.04.2024
Tilføjet 26.04.2024
This report describes the sensitivity of different kinds of tests that detect SARS-CoV-2, the virus that causes COVID-19.
Læs mereStatens Serum Institut, 25.04.2024
Tilføjet 25.04.2024
Bekæmpelsen af malaria er i de senere år gået den forkerte vej. Det skyldes blandt andet øget resistens, følger af covid-19-pandemien, de globale klimaforandringer og faldende finansiering til malariabekæmpelse. Introduktionen af de første malariavacciner i mange afrikanske lande i 2024 er et lille lyspunkt.
Læs mereMedscape Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
ECDC data show that measles and pertussis cases are on the rise again after a post–COVID-19 pandemic decline. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 19.04.2024
Tilføjet 19.04.2024
This report describes COVID-19 rates, hospitalizations, and vaccination coverage among nursing home residents.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 19.04.2024
Tilføjet 19.04.2024
This report describes the duration of protection provided by the original monovalent COVID-19 vaccines.
Læs mereECDC
ECDC COVID-19 updates, 17.04.2024
Tilføjet 17.04.2024
This report collects all COVID-19 long-term care facilities (LTCF) data reported to ECDC from 2021 and concludes the EU/EEA LTCF COVID-19 specific surveillance data collection from 2021-2023.
Læs mereMedscape Infectious Diseases, 15.04.2024
Tilføjet 15.04.2024
Primary care doctors who serve marginalized communities had the highest rate of patients unvaccinated against COVID-19 in a recent study. Medscape Medical News
Læs mereECDC
ECDC COVID-19 updates, 12.04.2024
Tilføjet 12.04.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 April 2024 and includes updates on measles, avian influenza, COVID-19, Mpox, seasonal influenza, RSV, cholera and shigellosis.
Læs mereECDC
ECDC Communicable Disease Threats Report, 12.04.2024
Tilføjet 12.04.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 April 2024 and includes updates on measles, avian influenza, COVID-19, Mpox, seasonal influenza, RSV, cholera and shigellosis.
Læs mereSarah K Nørgaard, Jens Nielsen, Anne Christine Nordholm, Lukas Richter, Alena Chalupka, Natalia Bustos Sierra, Toon Braeye, Maria Athanasiadou, Theodore Lytras, Gleb Denissov, Oskari Luomala, Anne Fouillet, Isabelle Pontais, Matthias an der Heiden, Benedikt Zacher, Alina Weigel, Ivo Foppa, Kassiani Gkolfinopoulou, Ioannis Panagoulias, Anna Paldy, Tibor Malnasi, Lisa Domegan, Eva Kelly, Naama Rotem, Oksana Rakhlin, Francesca K de'Donato, Chiara Di Blasi, Patrick Hoffmann, Telma Velez, Kathleen England, Neville Calleja, Liselotte van Asten, Femke Jongenotter, Ana Paula Rodrigues, Susana Silva, Petra Klepac, Diana Gomez-Barroso, Inmaculada Leon Gomez, Ilias Galanis, Ahmed Farah, Rolf Weitkunat, Katarina Fehst, Nick Andrews, Tom Clare, Declan T Bradley, Mark G O'Doherty, Naoma William, Mark Hamilton, Bolette Søborg, Tyra G Krause, Nick Bundle and Lasse S Vestergaard
Eurosurveillance latest updates, 12.04.2024
Tilføjet 12.04.2024
Since the end of November 2023, the European Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI: 91.7–98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 12.04.2024
Tilføjet 12.04.2024
This report describes a review of Oregon death certificate data to assess whether young people in Oregon might be dying after receiving a COVID-19 vaccine.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 12.04.2024
Tilføjet 12.04.2024
This report describes COVID-19 vaccination coverage in the World Health Organization African Region during 2021-2023.
Læs mereECDC
ECDC COVID-19 updates, 8.04.2024
Tilføjet 8.04.2024
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
Læs mereCiara Kelly, Joan Gallagher, Lola Odewumi, Robert Conway, Mary E Black, Kristin Concannon, Louise Marron and Lorraine Doherty
Eurosurveillance latest updates, 5.04.2024
Tilføjet 5.04.2024
The COVID-19 pandemic highlighted the importance of strengthening health protection worldwide. To address this as a public health priority in Ireland, between December 2021 and October 2022 the first national Health Protection Strategy (2022–2027) for the Irish Health Service Executive (HSE) was developed. We describe the approach taken to develop a first national health protection strategy for Ireland, and highlight the key lessons learned. Key steps in strategy formation included detailed stakeholder analysis, exploration of the context for the strategy and development of a comprehensive consultation plan. Two stakeholder consultation workshops were held. The first focused on defining strategic vision, aim and objectives, the second verified objectives and identified enablers. A subsequent e-consultation invited feedback from wider stakeholders. The published strategy outlines 10 strategic objectives and 11 enablers. Key lessons identified from the strategy development process include the importance of clear leadership and oversight, the value of identifying the context for change, ensuring adequate consultation planning, taking a multidisciplinary approach with strong stakeholder engagement and the need to maintain a strategic perspective. Lessons from our experience can support colleagues internationally to strategically set out their priorities for health protection beyond COVID-19.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 5.04.2024
Tilføjet 5.04.2024
This report describes the number of COVID-19 bivalent vaccine doses administered by Federal Retail Pharmacy Program partners.
Læs mereMedscape Infectious Diseases, 5.04.2024
Tilføjet 5.04.2024
Clinicians should still consider prescribing the drug to adults over age 65 or those who are immunocompromised, experts said. Medscape Medical News
Læs mereMedscape Infectious Diseases, 1.04.2024
Tilføjet 1.04.2024
The findings of this study, which focused on the early phases of the COVID-19 pandemic, may be useful to administrators and policymakers in case of a future pandemic outbreak. Medscape Medical News
Læs mereCharlotte Lanièce Delaunay, Iván Martínez-Baz, Noémie Sève, Lisa Domegan, Clara Mazagatos, Silke Buda, Adam Meijer, Irina Kislaya, Catalina Pascu, AnnaSara Carnahan, Beatrix Oroszi, Maja Ilić, Marine Maurel, Aryse Melo, Virginia Sandonis Martín, Camino Trobajo-Sanmartín, Vincent Enouf, Adele McKenna, Gloria Pérez-Gimeno, Luise Goerlitz, Marit de Lange, Ana Paula Rodrigues, Mihaela Lazar, Neus Latorre-Margalef, Gergő Túri, Jesús Castilla, Alessandra Falchi, Charlene Bennett, Virtudes Gallardo, Ralf Dürrwald, Dirk Eggink, Raquel Guiomar, Rodica Popescu, Maximilian Riess, Judit Krisztina Horváth, Itziar Casado, Mª del Carmen García, Mariëtte Hooiveld, Ausenda Machado, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling and on behalf of the European Primary Care Vaccine Effectiveness Group
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. MethodsThis European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. ResultsAmong adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%)
Læs mereWei Cai, Sophie Köndgen, Kristin Tolksdorf, Ralf Dürrwald, Ekkehard Schuler, Barbara Biere, Brunhilde Schweiger, Luise Goerlitz, Walter Haas, Thorsten Wolff, Silke Buda and Janine Reiche
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundNon-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. AimTo describe, for children aged
Læs mereMorbidity and Mortality Weekly Report (MMWR), 29.03.2024
Tilføjet 29.03.2024
This report describes the effectiveness of the updated COVID-19 vaccine in preventing hospitalizations in adults with immunocompromising conditions.
Læs mereMedscape Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
There is no increased risk for stroke during the 6 weeks following receipt of either brand of the COVID-19 bivalent vaccine, new research shows. Medscape Medical News
Læs mereMedscape Infectious Diseases, 26.03.2024
Tilføjet 26.03.2024
Inflammatory bowel disease therapies for patients may need to be briefly halted during treatment for COVID-19, but it does not increase flares. Medscape Medical News
Læs mereMedscape Infectious Diseases, 22.03.2024
Tilføjet 22.03.2024
Hospitalization for influenza raises the risk for future neurologic conditions more than hospitalization for COVID-19, the results of a large study showed. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 21.03.2024
Tilføjet 21.03.2024
This report describes trends in coccidioidomycosis, histoplasmosis, and blastomycosis cases during the COVID-19 pandemic.
Læs mere